Assertio Holdings

Rolvedon And Sympazan Will Open New Healthcare Frontiers

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

28 Apr 25

Updated

01 May 25

n/a

AnalystConsensusTarget's Fair Value

n/a

-21.9%

9.3%

-21.9%

9.3%

You can edit this narrative until May 12 6:02 AM. Then, changes will post as Updates.

Author's Valuation

US$2.6971.0% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates1

Shared on 01 May 25

Fair value Decreased 4.02%

AnalystConsensusTarget Fair Value

US$2.69

71.0% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

2.08%

Pharma revenue growth rate

0.67%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.96%

Calculation

US$15.73m

Earnings '28

20.38x

PE Ratio '28

US$320.62m

Market Cap '28

US$320.62m

Market Cap '28

98.47m

No. shares '28

US$3.26

Share Price '28

US$3.26 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$2.67

Fair Value '25